BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

17945

543064

COHANCE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Cohance Lifesciences Limited performance

Today’s low

Today’s high

₹ 974.90 ₹ 1007.40
₹ 1004.50

52 week low

52 week high

₹ 656.00 ₹ 1360.00
₹ 1004.50

Open Price

₹ 996.00

Prev. Close

₹ 1009.30

Volume (Shares)

284738.00

Total traded value

₹ 2860.19

Upper Circuit

₹ 1211.10

Lower Circuit

₹ 807.50

info

Cohance Lifesciences Limited Share Price Update

As of the latest trading session, Cohance Lifesciences Limited share price is currently at ₹ 1004.5, which is down by ₹ -4.79 from its previous closing. Today, the stock has fluctuated between ₹ 974.90 and ₹ 1007.40. Over the past year, Cohance Lifesciences Limited has achieved a return of 50.38 %. In the last month alone, the return has been -7.14 %. Read More...

Cohance Lifesciences Limited fundamentals


  • Market cap (Cr)

    38,428.90

  • P/E Ratio (TTM)

    141.39

  • Beta

    0.71

  • Book Value / share

    60.86

  • Return on equity

    14.31%

  • EPS (TTM)

    7.10

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    44.34

info icon alternate text
  • Market cap (Cr)

    38,404.00

  • P/E Ratio (TTM)

    141.39

  • Beta

    0.72

  • Book Value / share

    60.86

  • Return on equity

    14.31%

  • EPS (TTM)

    7.10

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    44.34

info icon alternate text

Cohance Lifesciences Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 330.17
Operating Expense 280.48
Net Profit 44.34
Net Profit Margin (%) 13.42
Earnings Per Share (EPS) 1.74
EBITDA 73.81
Effective Tax Rate (%) 21.27
Particulars DEC 2024 (Values in Cr)
Revenue 284.27
Operating Expense 188.55
Net Profit 83.67
Net Profit Margin (%) 29.43
Earnings Per Share (EPS) 3.29
EBITDA 128.72
Effective Tax Rate (%) 24.77
Particulars SEP 2024 (Values in Cr)
Revenue 236.06
Operating Expense 148.81
Net Profit 76.33
Net Profit Margin (%) 32.33
Earnings Per Share (EPS) 3.00
EBITDA 114.44
Effective Tax Rate (%) 24.18
Particulars JUN 2024 (Values in Cr)
Revenue 222.09
Operating Expense 152.65
Net Profit 65.07
Net Profit Margin (%) 29.29
Earnings Per Share (EPS) 2.56
EBITDA 100.99
Effective Tax Rate (%) 25.54
Particulars MAR 2024 (Values in Cr)
Revenue 252.93
Operating Expense 199.15
Net Profit 53.22
Net Profit Margin (%) 21.04
Earnings Per Share (EPS) 2.09
EBITDA 90.39
Effective Tax Rate (%) 24.87
Particulars MAR 2025 (Values in Cr)
Revenue 1093.51
Operating Expense 796.14
Net Profit 271.71
Net Profit Margin (%) 24.84
Earnings Per Share (EPS) 10.67
EBITDA 416.55
Effective Tax Rate (%) 22.66
Particulars MAR 2024 (Values in Cr)
Revenue 1051.35
Operating Expense 707.54
Net Profit 296.47
Net Profit Margin (%) 28.19
Earnings Per Share (EPS) 11.65
EBITDA 462.47
Effective Tax Rate (%) 25.96
Particulars MAR 2023 (Values in Cr)
Revenue 1330.08
Operating Expense 795.24
Net Profit 432.60
Net Profit Margin (%) 32.52
Earnings Per Share (EPS) 16.99
EBITDA 635.24
Effective Tax Rate (%) 25.33
Particulars MAR 2022 (Values in Cr)
Revenue 1320.22
Operating Expense 785.56
Net Profit 558.10
Net Profit Margin (%) 42.27
Earnings Per Share (EPS) 21.92
EBITDA 767.78
Effective Tax Rate (%) 22.74
Particulars MAR 2021 (Values in Cr)
Revenue 1009.72
Operating Expense 609.97
Net Profit 308.65
Net Profit Margin (%) 30.56
Earnings Per Share (EPS) 12.12
EBITDA 454.76
Effective Tax Rate (%) 25.44
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.56
ROE % 14.11
ROCE % 18.69
Total Debt to Total Equity 0.04
EBITDA Margin 40.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.16
ROE % 25.21
ROCE % 33.22
Total Debt to Total Equity 0.05
EBITDA Margin 46.30
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.99
ROE % 29.79
ROCE % 40.62
Total Debt to Total Equity 0.09
EBITDA Margin 48.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 46.38
ROE % 35.78
ROCE % 40.45
Total Debt to Total Equity 0.16
EBITDA Margin 50.61
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.37
ROE % 44.58
ROCE % 49.77
Total Debt to Total Equity 0.19
EBITDA Margin 54.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.76
ROE % 14.31
ROCE % 18.82
Total Debt to Total Equity 0.04
EBITDA Margin 41.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.72
ROE % 26.46
ROCE % 34.28
Total Debt to Total Equity 0.05
EBITDA Margin 47.76
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.74
ROE % 43.17
ROCE % 51.45
Total Debt to Total Equity 0.09
EBITDA Margin 58.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.84
ROE % 33.40
ROCE % 38.83
Total Debt to Total Equity 0.18
EBITDA Margin 45.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 61.50
ROE % 39.71
ROCE % 45.81
Total Debt to Total Equity 0.20
EBITDA Margin 48.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 50.49
Total Assets 2254.08
Total Liabilities 2254.08
Total Equity 2050.66
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.32
Return on Capital (%) 14.37
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 68.01
Total Assets 1965.74
Total Liabilities 1965.74
Total Equity 1735.18
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 20.92
Return on Capital (%) 22.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.30
Total Assets 1829.58
Total Liabilities 1829.58
Total Equity 1527.18
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 24.80
Return on Capital (%) 27.97
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 1474.47
Total Liabilities 1474.47
Total Equity 1180.79
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 24.57
Return on Capital (%) 27.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 14.07
Total Assets 1172.81
Total Liabilities 1172.81
Total Equity 844.76
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 27.02
Return on Capital (%) 30.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 21.58
Total Assets 2240.71
Total Liabilities 2240.71
Total Equity 2055.89
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.60
Return on Capital (%) 14.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 46.23
Total Assets 1958.33
Total Liabilities 1958.33
Total Equity 1749.38
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 22.09
Return on Capital (%) 23.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 32.95
Total Assets 1804.88
Total Liabilities 1804.88
Total Equity 1520.69
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 30.92
Return on Capital (%) 34.53
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 1358.82
Total Liabilities 1358.82
Total Equity 1065.18
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 22.71
Return on Capital (%) 25.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 13.95
Total Assets 1110.88
Total Liabilities 1110.88
Total Equity 782.82
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 24.31
Return on Capital (%) 27.9
Particulars MAR 2024 (Values in Cr)
Net Income 405.67
Cash from Operations 468.43
Cash from Investing -362.25
Cash from Financing -13.80
Net change in Cash -17.57
Free Cash Flow 520.22
Particulars MAR 2023 (Values in Cr)
Net Income 559.72
Cash from Operations 602.95
Cash from Investing -195.00
Cash from Financing -241.95
Net change in Cash 20.23
Free Cash Flow 888.86
Particulars MAR 2022 (Values in Cr)
Net Income 667.58
Cash from Operations 514.25
Cash from Investing -136.13
Cash from Financing -156.48
Net change in Cash 37.38
Free Cash Flow 589.44
Particulars MAR 2021 (Values in Cr)
Net Income 467.67
Cash from Operations 491.98
Cash from Investing -311.39
Cash from Financing -75.66
Net change in Cash -4.51
Free Cash Flow 602.82
Particulars MAR 2020 (Values in Cr)
Net Income 404.51
Cash from Operations 493.32
Cash from Investing -413.44
Cash from Financing 7.32
Net change in Cash 0.79
Free Cash Flow 596.39
Particulars MAR 2024 (Values in Cr)
Net Income 408.77
Cash from Operations 479.16
Cash from Investing -381.57
Cash from Financing -13.77
Net change in Cash -24.70
Free Cash Flow 529.48
Particulars MAR 2023 (Values in Cr)
Net Income 579.39
Cash from Operations 638.60
Cash from Investing -236.86
Cash from Financing -243.14
Net change in Cash 12.81
Free Cash Flow 783.21
Particulars MAR 2022 (Values in Cr)
Net Income 722.44
Cash from Operations 421.63
Cash from Investing -90.36
Cash from Financing -156.41
Net change in Cash 23.11
Free Cash Flow 496.82
Particulars MAR 2021 (Values in Cr)
Net Income 413.97
Cash from Operations 438.27
Cash from Investing -257.65
Cash from Financing -75.66
Net change in Cash -4.48
Free Cash Flow 549.11
Particulars MAR 2020 (Values in Cr)
Net Income 357.59
Cash from Operations 445.15
Cash from Investing -366.64
Cash from Financing 8.57
Net change in Cash 0.67
Free Cash Flow 548.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

Cohance Lifesciences Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1004.50 -0.47 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1013.70
  • 26 Days 1055.10
  • 10 Days 1026.00
  • 50 Days 1081.10
  • 12 Days 1030.40
  • 100 Days 1101.90
  • 20 Days 1045.80
  • 200 Days 1075.00
1016.87 PIVOT

First Support

989.83

First Resistance

1036.33

Second Support

970.37

Second Resistance

1063.37

Third Support

943.33

Third Resistance

1082.83

RSI

37.65

ADX

35.53

MACD

-24.74

Williams % R

-79.46

Commodity Channel Index (CCI)

-139.33

Date

2025-06-13

Week

176737.00

Same Day

142338.00

Month

159463.00

1 Year

0.72

3 Year

0.43

Over 1 Month

-7.14%

down

Over 1 Year

50.38%

down

Over 3 Months

-12.55%

down

Over 3 Years

28.34%

down

Over 6 Months

-20.90%

down

Over 5 Years

43.52%

down

Cohance Lifesciences Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
15.18%
Promoter Holdings
66.41%
FII
7.38%
DII
11.01%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Berhyanda Limited 1.27539592E8 (33.34%) Shareholding of Promoter and Promoter Group
Jusmiral Holdings Limited 1.26538578E8 (33.08%) Shareholding of Promoter and Promoter Group
Jasti Property And Equity Holdings Private Limited 2.5192957E7 (6.59%) Public Shareholding
Dsp Regular Savings Fund 1.0703962E7 (2.8%) Public Shareholding
Sbi Life Insurance Co. Ltd 7544965.0 (1.97%) Public Shareholding
Invesco India Focused Fund 4519688.0 (1.18%) Public Shareholding

News

Left Arrow
Right Arrow

Cohance Lifesciences Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
13 May 2022 1.0 Special 17 May 2022 Equity shares
15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
Ex-Date Ex-Bonus Ratio
28 Sep 2020 25 Sep 2020 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
13 May 2022 1.0 Special 17 May 2022 Equity shares
15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
Ex-Date Ex-Bonus Ratio
28 Sep 2020 25 Sep 2020 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Cohance Lifesciences Limited Share Price

Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D,
Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations.

Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.

In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.

The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.

The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.

During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.

As on 31 March 2020,the company has one subsidiary and one associate company under its roof.

The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.

The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..

In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.

During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Parent organization Indian Private
NSE symbol COHANCE
Founded 2018
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Cohance Lifesciences Ltd?

Answer Field

The share price of Cohance Lifesciences Ltd for NSE is ₹ 1,004.50 and for BSE is ₹ 1,006.70.

What is the Market Cap of Cohance Lifesciences Ltd?

Answer Field

The market cap of Cohance Lifesciences Ltd for NSE is ₹ 25,571.05 Cr. and for BSE is ₹ 25,627.05 Cr. as of now.

What is the 52 Week High and Low of Cohance Lifesciences Ltd?

Answer Field

The 52 Week High and Low of Cohance Lifesciences Ltd for NSE is ₹ 1,360.00 and ₹ 656.00 and for BSE is ₹ 1,359.00 and ₹ 656.35.

How to Buy Cohance Lifesciences Ltd share?

Answer Field

You can trade in Cohance Lifesciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Cohance Lifesciences Ltd?

Answer Field

The 1 year returns on the stock has been 50.38%.

What is the Current Share Price of Cohance Lifesciences Ltd?

Answer Field

Cohance Lifesciences Ltd share price is for NSE ₹ 1,004.50 & for BSE ₹ 1,006.70 as on Jun 13 2025 03:30 PM.

What is the Market Cap of Cohance Lifesciences Ltd Share?

Answer Field

The market cap of Cohance Lifesciences Ltd for NSE ₹ 25,571.05 & for BSE ₹ 25,627.05 as on Jun 13 2025 03:30 PM.

What is the P/E Ratio of Cohance Lifesciences Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Cohance Lifesciences Ltd share is 141.39.

What is the PB ratio of Cohance Lifesciences Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Cohance Lifesciences Ltd share is 60.86.

How to Buy Cohance Lifesciences Ltd Share?

Answer Field

You can trade in Cohance Lifesciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Cohance Lifesciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Cohance Lifesciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Cohance Lifesciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|